• Biography

    Ben Pelletier is a partner in the Precision Medicine and Digital Health Practice Group in Haynes and Boone’s San Francisco office.

    His practice focuses on advising clients in the complex and fast-evolving areas of biology, medicine, engineering, and data science. Ben has significant experience building patent portfolios relating to monoclonal antibodies and antibody-drug conjugates (ADCs), CAR-T cells, stem cells, tissue engineering, 3D bioprinting, biosensors, genomic sequencing, and bioinformatics, as well as companion diagnostic assay systems and devices.

    He has helped many clients develop and protect their intellectual property in the immuno-oncology space, with a particular focus on cellular therapeutics, bispecific T-cell engagers (TCEs) and other large molecule compositions.

    Ben holds an advanced degree in bioengineering, and spent many years working at a leading biotechnology company as an engineer and project manager before attending law school. Prior to Haynes and Boone, Ben was a patent attorney at an international law firm, where he managed several global patent portfolios for a pharmaceutical company and helped a life science company plan and build its patent strategy and portfolio from the ground up.

    Whether interviewing inventors to identify patentable subject matter, or invalidating the claims of a competitor's patent in an inter partes review (IPR) proceeding, Ben brings an affinity for technology and a hands-on approach to every project. He understands his clients' technology, their business models, and their products and services.

    Professional Recognition

    • Northern California Super Lawyers Rising Star, Thomson Reuters, 2019–2020
    • The Legal 500 U.S., Legalese Ltd., Intellectual Property – Patents: Prosecution (including re-examination and post-grant proceedings), 2019

    Selected Client Representations

    • Represented and advised TeneoBio, Inc. and its affiliate, TeneoOne, Inc., as it entered into a strategic transaction with AbbVie, Inc. to develop and commercialize a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.

    Selected Publications and Speeches

    • “Did the Supreme Court Get It Right?: A Discussion of the Implications of Helsinn v. Teva on the Biotech/Pharma Industry, presenter, Rancho Palos Verdes, CA, April 26-28, 2019
  • Education and Clerkships

    • J.D., University of California, Hastings College of Law, 2010
    • Master of Engineering Science, Bioengineering, University of California, San Diego, 2001
    • B.S., Bioengineering, University of California, Berkeley, 2000
  • Admissions

    • California
    • U.S. Patent and Trademark Office
  • Languages

    • Spanish